Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study

Young-Gun Kim,J. Jeon,S. Han,D. Kim,K. Lee,H. Kim
DOI: https://doi.org/10.1111/dom.13297
2018-08-01
Diabetes, Obesity and Metabolism
Abstract:To estimate the risk of diabetic ketoacidosis (DKA) associated with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor treatment compared with the risk associated with dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor treatment.
What problem does this paper attempt to address?